Author

Zachary K. Sagawa

Observed names: Zachary K Sagawa, Zachary Sagawa

Institution: Access to Advanced Health Institute

Observed institutions: Infectious Disease Research Institute, Duke University, University of Washington, Duke Medical Center, Johnson County Clin-Trials (United States), Access to Advanced Health Institute, Rockefeller University

ORCID: 0009-0001-9846-211X

Observed ORCID: 0009-0001-9846-211X

OpenAlex ID: A5001274600

Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5

2001 · James A. Bibb, Jingshan Chen, et al. · Nature · 483

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

2018 · Rhea N. Coler, Tracey A. Day, et al. · npj Vaccines · 175

Monocyte Chemoattractant Protein-1 Deficiency Fails to Restrain Macrophage Infiltration Into Adipose Tissue

2008 · Elizabeth A. Kirk, Zachary K. Sagawa, et al. · Diabetes · 156

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial

2020 · Tracey A Day, Adam Penn-Nicholson, et al. · The Lancet Respiratory Medicine · 103

A structure‐function approach to optimizing TLR4 ligands for human vaccines

2016 · Darrick Carter, Christopher B Fox, et al. · Clinical & Translational Immunology · 58

The adjuvant GLA-AF enhances human intradermal vaccine responses

2018 · Darrick Carter, Neal van Hoeven, et al. · Science Advances · 48

Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies

2024 · William O. Hahn, K. Rachael Parks, et al. · The Journal of Experimental Medicine · 44

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults

2023 · Zachary K. Sagawa, Cristina Goman, et al. · Nature Communications · 43

A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA–SE) in healthy adults

2019 · Malcolm S. Duthie, Aude Frevol, et al. · Vaccine · 35

An HIV-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals

2024 · Nathaniel Erdmann, Wilton B. Williams, et al. · medRxiv · 12

Safety and implementation of phase I randomized GLA-SE–adjuvanted CH505TF gp120 HIV vaccine trial in newborns

2025 · Avy Violari, Kennedy Otwombe, et al. · Journal of Clinical Investigation · 9

Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)

2026 · Stephen Walsh, William O Hahn, et al. · medRxiv · 5

Abstract CT201: Early report of a phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19 (NCT04365101)

2021 · Corey Casper, Leonid Groysman, et al. · Cancer Research · 5

Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans

2024 · Andrew Fiore-Gartland, Himangi Srivastava, et al. · Frontiers in Immunology · 3

Works count: 14

Citation count: 1,179

H-index: 10

I10-index: 10